Optimizing human α-galactosidase for treatment of Fabry disease

• Published in: Scientific reports Vol. 13; no. 1; p. 4748
• Main Authors: Hallows, William C., Skvorak, Kristen, Agard, Nick, Kruse, Nikki, Zhang, Xiyun, Zhu, Yu, Botham, Rachel C., Chng, Chinping, Shukla, Charu, Lao, Jessica, Miller, Mathew, Sero, Antoinette, Viduya, Judy, Ismaili, Moulay Hicham Alaoui, McCluskie, Kerryn, Schiffmann, Raphael, Silverman, Adam P., Shen, Jin-Song, Huisman, Gjalt W.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.03.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/45; 639/166/985; 692/4017; alpha-Galactosidase - genetics; alpha-Galactosidase - metabolism; Amino acids; Animals; Blood vessels; Directed evolution; Disease; Disease Models, Animal; Enzymatic activity; Enzymes; Fabry Disease - drug therapy; Fabry Disease - genetics; Fabry's disease; Fibroblasts; Fibroblasts - metabolism; Globotriaosylceramide; Glycosphingolipids; Humanities and Social Sciences; Humans; Immunogenicity; Kidney - metabolism; Kidneys; Lysosomal storage diseases; Major histocompatibility complex; Mice; multidisciplinary; Peptides; Pharmacokinetics; Proteomics; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-31777-4

Fabry disease is caused by a deficiency of α-galactosidase A (GLA) leading to the lysosomal accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids. Fabry patients experience significant damage to the heart, kidney, and blood vessels that can be fatal. Here we apply directed evolution to generate more stable GLA variants as potential next generation treatments for Fabry disease. GLAv05 and GLAv09 were identified after screening more than 12,000 GLA variants through 8 rounds of directed evolution. Both GLAv05 and GLAv09 exhibit increased stability at both lysosomal and blood pH, stability to serum, and elevated enzyme activity in treated Fabry fibroblasts (19-fold) and GLA –/– podocytes (10-fold). GLAv05 and GLAv09 show improved pharmacokinetics in mouse and non-human primates. In a Fabry mouse model, the optimized variants showed prolonged half-lives in serum and relevant tissues, and a decrease of accumulated Gb3 in heart and kidney. To explore the possibility of diminishing the immunogenic potential of rhGLA, amino acid residues in sequences predicted to bind MHC II were targeted in late rounds of GLAv09 directed evolution. An MHC II-associated peptide proteomics assay confirmed a reduction in displayed peptides for GLAv09. Collectively, our findings highlight the promise of using directed evolution to generate enzyme variants for more effective treatment of lysosomal storage diseases.